A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
Conditions: ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC) Interventions: Drug: AZD8421; Drug: Camizestrant; Drug: Ribociclib; Drug: Palbociclib; Drug: Abemaciclib Sponsors: AstraZeneca Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Ovarian Cancer | Ovaries | Research | Study